Targeted Therapy of Respiratory Syncytial Virus by 2_5A Antisense

By Cramer Hagen   Okicki James   Kuang Mei   Xu Zan  

Nucleosides, Nucleotides & Nucleic Acids, Vol. 24, Iss. 5-7, 2005-04 ,pp. : 497-501

Taylor & Francis Ltd

Access to resources Recommend Favorite

Carriers for the delivery of a vaccine against respiratory syncytial virus

By Cranage Martin   Taylor Geraldine  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 7, 2005-07 ,pp. : 939-952

Informa Healthcare

Access to resources Recommend Favorite

Motavizumab for the prevention of respiratory syncytial virus infection in infants

By Gill Michelle A   Welliver Robert C  

Expert Opinion on Biological Therapy, Vol. 9, Iss. 10, 2009-10 ,pp. : 1335-1345

Informa Healthcare

Access to resources Recommend Favorite

Palivizumab in the prevention of respiratory syncytial virus disease

By Krilov Leonard R  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 7, 2002-10 ,pp. : 763-769

Informa Healthcare

Access to resources Recommend Favorite

A review of palivizumab and emerging therapies for respiratory syncytial virus

By Shadman Kristin A   Wald Ellen R  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 11, 2011-11 ,pp. : 1455-1467

Informa Healthcare

Access to resources Recommend Favorite